SignalXSignalX

CHRS Coherus Oncology, Inc.

8-K Current Report
Filed: March 9, 2026
Health Care
Biological Products, (No Diagnostic Substances)
Coherus Oncology, Inc. Overview

Coherus Oncology, Inc. (CHRS) 8-K current report filed with SEC EDGAR on March 9, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
1 item

  • Item 2.02: Results of Operations and Financial Condition

AI Filing Analysis
8-K

Item 2.02 · Results of Operations and Financial Condition

  • • Q4 and full-year 2025 financial results released March 9, 2026
  • • Full earnings details in Exhibit 99.1 — primary source for revenue, margins, and guidance figures

Get deeper insights on Coherus Oncology, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.